Ссылки
1. Mundy A. Dispensing with the Truth. New York: St. Martin’s Press; 2001.
2. Angell M. The Truth about the Drug Companies: how they deceive us and what to do about it. New York: Random House; 2004.
3. Day M. Don’t blame it all on the bogey. BMJ. 2007; 334: 1250–1.
4. Bailey R.S. FDA corruption charges letter verified. The Los Angeles Post. 2012 April 8.
5. Tanne J.H. Investigators to review conflicts of interest at NIH. BMJ. 2007; 334: 767.
6. Tanne J.H. Former FDA head is fined $90 000 for failing to disclose conflicts of interest. BMJ. 2007; 334: 492.
7. Andersen N.A., Drachmann H. [Psychiatrist gets millions]. Politiken. 2003 Dec 5.
8. Braithwaite J. Corporate Crime in the Pharmaceutical Industry. London: Routledge & Kegan Paul; 1984.
9. Blowing the whistle on the FDA: an interview with David Graham. Multinational Monitor 2004; 25(12).
10. Lenzer J. Crisis deepens at the US Food and Drug Administration. BMJ. 2004; 329: 1308.
11. Moynihan R., Cassels A. Selling Sickness: how the world’s biggest pharmaceutical companies are turning us all into patients. New York: Nation Books; 2005.
12. Ross D.B. The FDA and the case of Ketek. N Engl J Med. 2007; 356: 1601–4.
13. Baciu A., Stratton K., Burke S.P., eds. The Future of Drug Safety: promoting and protecting the health of the public. Washington, DC: National Academies Press; 2006.
14. Smith S.W. Sidelining safety – the FDA’s inadequate response to the IOM. N Engl J Med. 2007; 357: 960–3.
15. Willman D. How a new policy led to seven deadly drugs. Los Angeles Times. 2000 Dec 20.
16. Abraham J. Science, Politics and the Pharmaceutical Industry. London: UCL Press; 1995.
17. House of Commons Health Committee. The Influence of the Pharmaceutical Industry. Fourth Report of Session 2004–05. Available online at: www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf (accessed 26 April 2005).
18. Graham D.J. COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense. JAMA. 2006; 296: 1653–6.
19. J?ni P., Nartey L., Reichenbach S., et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004; 364: 2021–9.
20. Garattini S. Confidentiality. Lancet. 2003; 362: 1078–9.
21. Union of Concerned Scientists. FDA Scientists Pressured to Exclude, Alter Findings; scientists fear retaliation for voicing safety concerns. 2006 July 20.
22. Psaty B.M., Burke S.P. Institute of Medicine on drug safety. N Engl J Med. 2006; 355: 1753–5.
23. Anonymous. Institute of Medicine urges reforms at FDA. Lancet. 2006; 368: 1211.
24. Strom B.L. How the US drug safety system should be changed. JAMA. 2006; 295: 2072–5.
25. Abramson J. Overdo$ed America: the broken promise of American medicine. New York: HarperCollins; 2004.
26. United States General Accounting Office. Food and Drug Administration: effect of user fees on drug approval times, withdrawals, and other agency activities. Sept 2002.
27. Reuters. Danish drugmaker Lundbeck A/S and Japanese partner Takeda Pharmaceutical Co have submitted a new antidepressant for regulatory approval in the United States. 2012 Oct 2.
28. Avorn J., Shrank W. Highlights and a hidden hazard – the FDA’s new labeling regulations. N Engl J Med. 2006; 354: 2409–11.
29. Letter from FDA scientists to President Barrack Obama. 2009 Apr 2. Available online at: http://gaia-health.com/articles201/000201-letter.pdf (accessed 11 Nov 2012).
30. Lichtblau E., Shane S. Vast FDA effort tracked e-mails of its scientists. New York Times. 2012 July 14.
31. Rosenberg M. Former FDA reviewer speaks out about intimidation, retaliation and marginalizing of safety. Truthout. 2012 July 29.
32. Brynner R., Stephens T. Dark Remedy: the impact of thalidomide and its revival as a vital medicine. New York: Perseus Publishing; 2001.
33. Brody H. Hooked: ethics, the medical profession, and the pharmaceutical industry. Lanham: Rowman & Littlefi eld; 2008.
34. Sibbison J.B. USA: dirty work in the drug industry. Lancet. 1991; 337: 227.
35. Wikipedia. Duilio Poggiolini. Available online at: http://en.wikipedia.org/wiki/Duilio_Poggiolini (accessed 10 November 2012).
36. Abbott A. Italian health sector in disarray following more scandals. Nature. 1993; 364: 663.
37. Medawar C., Hardon A. Medicines out of control? Antidepressants and the conspiracy of goodwill. Netherlands: Aksant Academic Publishers; 2004.
38. Day M. Italian police arrest drug offi cials over alleged falsifi cation of data. BMJ. 2008; 336: 1208–9.
39. Pfizer memoranda, 24 and 26 April 1989.
40. Grill M. Kranke Gesch?fte: wie die Pharmaindustrie uns manipuliert. Hamburg: Rowohlt Verlag; 2007.
41. Relman A.S., Angell M. America’s other drug problem: how the drug industry distorts medicine and politics. The New Republic. 2002 Dec 16: 27–41.
42. Ismail M. Drug Lobby Second to None: how the pharmaceutical industry gets its way in Washington. The Center for Public Integrity. 2005 July 7.
43. Bass A. Side Effects – a prosecutor, a whistleblower, and a bestselling antidepressant on trial. Chapel Hill: Algonquin Books; 2008.
44. G?tzsche P.C., J?rgensen A.W. Opening up data at the European Medicines Agency. BMJ. 2011; 342: d2686.
45. Anonymous. FDA more transparent than EMEA. Prescrire International. 2002; 11: 98.
46. Garattini S., Bertele V. How can we regulate medicines better? BMJ. 2007; 335: 803–5.
47. Kranish M. Drug industry costs doctor top FDA post. Boston Globe. 2002 May 27.
48. Goozner M. The $800 Million Pill: the truth behind the cost of new drugs. Berkeley: University of California Press; 2005.
49. McClellan M.B. Speech before First International Colloquium on Generic Medicine. Available online at: www.fda.gov/oc/speeches/2003/genericdrug0925.html (accessed 18 February 2008).
50. Carpenter D., Zucker E.J., Avorn J. Drug-review deadlines and safety problems. N Engl J Med. 2008; 358: 1354–61.
51. Carpenter D. Drug-review deadlines and safety problems (authors’ reply). N Engl J Med. 2008; 359: 96–8.
52. Moore T.J., Cohen M.R., Furberg C.D. Serious adverse drug events reported to the Food and Drug Administration, 1998–2005. Arch Intern Med. 2007; 167: 1752–9.
53. Lexchin J. New drugs and safety: what happened to new active substances approved in Canada between 1995 and 2010? Arch Intern Med. 2012 Oct 8: 1–2.
54. Avorn J. Paying for drug approvals – who’s using whom? N Engl J Med. 2007; 356: 1697–700.
55. Psaty B.M., Korn D. Congress responds to the IOM drug safety report – in full. JAMA. 2007; 298: 2185–7.
56. Harris G., Halbfinger D.M. FDA reveals it fell to a push by lawmakers. New York Times. 2009 Sept 25.
57. Dhruva S.S., Bero L.A., Redberg R.F. Strength of study evidence examined by the FDA in premarket approval of cardiovascular devices. JAMA. 2009; 302: 2679–85.
58. Van Brabandt H., Neyt M., Hulstaert F. Transcatheter aortic valve implantation (TAVI): risky and costly. BMJ. 2012; 345: e4710.
59. Collier J. Big pharma and the UK government. Lancet. 2006; 367: 97–8.
60. Lee K., Bacchetti P., Sim I. Publication of clinical trials supporting successful new drug applications: a literature analysis. PLoS Med. 2008; 5: e191.
61. European Commission. Strategy to Better Protect Public Health by Strengthening and Rationalising EU Pharmacovigilance. 2007 Dec 5.
62. HAI Europe. Pharmacovigilance in Europe and Patient Safety: no to deregulation. Press release. 2008 Feb 1.
63. Larsen H., Nyborg S. [The drug industry asks for control]. Politiken. 2006 Mar 5.
64. [Committee on Scientifi c Dishonesty tamed]. Ugeskr L?ger. 2005; 167: 3476–7.
65. Greene J.A., Choudhry N.K., Kesselheim A.S., et al. Changes in direct-to-consumer pharmaceutical advertising following shifts from prescription-only to over-the-counter status. JAMA. 2012; 308: 973–5.
66. Welch H.G. Should I be Tested for Cancer? Maybe not and here’s why. Berkeley: University of California Press; 2004.
67. Welch H.G., Schwartz L., Woloshin S. Overdiagnosed: making people sick in the pursuit of health. Boston, MA: Beacon Press; 2011.
68. Andersen N.V. [Drug giant uses American pressure in Danish drug case]. Politiken. 2004 Aug 31.
69. Amendment to the Federal Food, Drug and Cosmetic Act. Washington, DC: 4 Jan, 2007. Available online at: www.fda.gov/oc/initiatives/HR3580.pdf (accessed 8 July 2008).
70. Moore T.J., Furberg C.D. The safety risks of innovation: the FDA’s Expedited Drug Development Pathway. JAMA. 2012; 308: 869–70.
71. Jefferson T., Jones M.A., Doshi P., et al. Neuraminidase inhibitors for preventing and treating infl uenza in healthy adults and children. Cochrane Database Syst Rev. 2012; 1: CD008965.
72. Meier B. Contracts keep drug research out of reach. New York Times. 2004 Nov 29.
73. Lurie P., Wolfe S.M. Misleading data analyses in salmeterol (SMART) study. Lancet. 2005; 366: 1261–2.
74. Rickard K.A. Misleading data analyses in salmeterol (SMART) study – GlaxoSmithKline’s reply. Lancet. 2005; 366: 1262.
75. Castle W., Fuller R., Hall J., et al. Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment. BMJ. 1993; 306: 1034–7.
76. Salpeter S.R., Buckley N.S., Ormiston T.M., et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern Med. 2006; 144: 904–12.
77. FDA Drug Safety Communication: new safety requirements for long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs). 2010 Feb 18. Available online at: www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ ucm200776.htm (accessed 8 October 2012).
78. Nelson H.S., Weiss S.T., Bleecker E.R., et al. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest. 2006; 129: 15–26.
79. Curfman G.D., Morrissey S., Drazen J.M. Products at risk. N Engl J Med. 2010; 363: 1763.
80. Harris G. Pfi zer says internal studies show no Celebrex risks. New York Times. 2005 Feb 5.
81. Caldwell B., Aldington S., Weatherall M., et al. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006; 99: 132–40.
82. Sherman M., Marchione M. Pfizer: Celebrex raises heart attack risk. ABC News. 2004 Dec 17.
83. Avorn J. Powerful Medicines: the benefits, risks, and costs of prescription drugs. New York: Vintage Books; 2005.
84. Avorn J. Dangerous deception – hiding the evidence of adverse drug effects. N Engl J Med. 2006; 355: 2169–71.
85. Petersen M. Our Daily Meds. New York: Sarah Crichton Books; 2008.
86. Whitaker R. Anatomy of an Epidemic. New York: Broadway Paperbacks; 2010.
87. Smith S.M., Schroeder K., Fahey T. Over-the-counter (OTC) medications for acute cough in children and adults in ambulatory settings. Cochrane Database Syst Rev. 2012; 8: CD001831.
88. Tomerak A.A.T., Vyas H.H.V., Lakhanpaul M., et al. Inhaled beta2-agonists for non-specific chronic cough in children. Cochrane Database Syst Rev. 2005; 3: CD005373.
89. Glintborg D. [Cough medicines for acute respiratory infections, what is the evidence?] Rationel Farmakoterapi. 2003 Jan 4.
90. Sharfstein J.M., North M., Serwint J.R. Over the counter but no longer under the radar – pediatric cough and cold medications. N Engl J Med. 2007; 357: 2321–4.
91. Public Health Advisory: FDA Recommends that Over-the-Counter (OTC) Cough and Cold Products not be used for Infants and Children under 2 Years of Age. 2011 Feb 23.
92. Parvez L., Vaidya M., Sakhardande A., et al. Evaluation of antitussive agents in man. Pulm Pharmacol. 1996; 9: 299–308.
93. Goodyear M.D., Lemmens T., Sprumont D., et al. Does the FDA have the authority to trump the Declaration of Helsinki? BMJ. 2009; 338: b1559.
94. Wikipedia. Tuskegee syphilis experiment. Available online at: http://en.wikipedia.org/wiki/Tuskegee_syphilis_experiment (accessed 21 January 2010).
95. Boseley S., Smith D. As doctors fought to save lives, Pfizer flew in drug trial team. The Guardian. 2010 Dec 9.
96. Smith D. Pfizer pays out to Nigerian families of meningitis drug trial victims. The Guardian. 2011 Aug 12.
97. Chalmers T.C., Frank C.S., Reitman D. Minimizing the three stages of publication bias. JAMA. 1990; 263: 1392–5.
98. The Coronary Drug Project Research Group. Influence of adherence to treatment and response of cholesterol on mortality in the coronary drug project. N Engl J Med. 1980; 303: 1038–41.
99. Nissen S.E. Cardiovascular effects of diabetes drugs: emerging from the dark ages. Ann Intern Med. 2012; 157: 671–2.
100. G?tzsche P.C., Liberati A., Luca P., et al. Beware of surrogate outcome measures. Int J Technol Ass Health Care. 1996; 12: 238–46.
101. Pocock S.J. When to stop a clinical trial. BMJ. 1992; 305: 235–40.
102. Moore T.J. Deadly Medicine: why tens of thousands of heart patients died in America’s worst drug disaster. New York: Simon & Schuster; 1995.
103. G?tzsche P.C., J?rgensen K.J. Screening for breast cancer with mammography. Cochrane Database Syst Rev. 2013; 6: CD001877.
104. D’Agostino R.B. Sr. Changing end points in breast-cancer drug approval – the Avastin story. N Engl J Med. 2011; 365: e2.
105. Pollack A. FDA revokes approval of Avastatin for use as breast cancer drug. New York Times. 2011 Nov 18.
106. Lenzer J. FDA is criticised for hinting it may loosen conflict of interest rules. BMJ. 2011; 343: d5070.
107. Psaty B.M., Lumley T. Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs. JAMA. 2008; 299: 1474–6.
108. Heavey S. FDA warns Pfizer for not reporting side effects. Reuters. 2010 June 10.
109. Wise J. European drug agency criticises Roche for failing to report adverse reactions and patient deaths. BMJ. 2012; 344: e4344.
110. McCartney M. Statins for all? BMJ. 2012; 345: e6044.
111. Golomb B.A., Evans M.A., Dimsdale J.E., et al. Effects of statins on energy and fatigue with exertion: results from a randomized controlled trial. Arch Intern Med. 2012; 172: 1180–2.
112. St?vring H., Harmsen C.G., Wisl?ff T., et al. A competing risk approach for the European Heart SCORE model based on cause-specifi c and all-cause mortality. Eur J Prev Cardiol. 2012 Apr 12.
113. Hampton T. Flawed prescribing practices revealed. JAMA. 2006; 296: 2191–2.
114. Smalley W., Shatin D., Wysowski D.K., et al. Contraindicated use of cisapride: impact of food and drug administration regulatory action. JAMA. 2000; 284: 3036–9.
115. Kingston A. A national embarrassment. Maclean’s Magazine. 2012 Oct 17.
116. Kragh A. [Two of three people in nursing homes are in treatment with at least ten drugs]. L?kartidningen. 2004; 101: 994–9.
117. Garfinkel D., Mangin D. Feasibility study of a systematic approach for discontinuation of multiple medications in older adults: addressing polypharmacy. Arch Intern Med. 2010; 170: 1648–54.
118. Mann H. Beware of polypharmacy in the elderly. BMJ. 2009 March 8. Available online at: www.bmj.com/cgi/eletters/338/mar03_2/b873 (accessed 12 March 2009).
119. Moynihan R. Is your mum on drugs? BMJ. 2011; 343: d5184.
120. Goodwin J.S. Geriatrics and the limits of modern medicine. N Engl J Med. 1999; 340: 1283–5.
